Background: Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC).
Methods: 49 patients with previously untreated mCRC were recruited. Nineteen received capecitabine (1750 mg/m(2) oral BD days 1-7)oxaliplatin (85 mg/m(2)i.v. day 1) and bevacizumab (5 mg/kg i.v. day 1) using a 14-day cycle (C1750). Following toxicity concerns capecitabine was reduced to 1500 mg/m2oral BD (C1500) and 30 further patients recruited.
Results: Over 80% of patients received at least 75% of planned chemotherapy doses over the first two cycles. At C1750 Grade 3 or higher toxicity occurred in 74% (95% CI 49% to 91%) and on C1500 in 70% (95% CI 51% to 85%). The median progression-free survival was 6.9 months (95% CI 4.7 to 8.7) for C1750 dose and 8.9 months (95% CI 4.1 to 12.4) for C1500. 3 treatment-related deaths occurred.
Conclusions: Dose intense capecitabine and oxaliplatin with bevacizumab does not show additional efficacy and has potentially significant toxicity. Its use outside of clinical trials is not recommended.
Trial Registration: ISRCTN41540878.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192459 | PMC |
| http://dx.doi.org/10.1186/1471-2407-14-737 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prophylactic use of duloxetine hydrochloride in oxaliplatin-induced first-bite syndrome.
Int Cancer Conf J
January 2025
Department of Otolaryngology-Head and Neck Surgery, Kagawa Rosai Hospital, Kagawa, Japan.
First-bite syndrome (FBS) is manifested as acute and severe pain in the parotid region occurring at the first bite of a meal. While most cases of FBS arise after surgeries involving the deep lobe of the parotid gland, chemotherapy-induced FBS is extremely rare. Some adverse effects of oxaliplatin resemble FBS, suggesting it may be under-recognized.
View Article and Find Full Text PDFValue of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial).
BMJ Open
January 2025
Colorectal Cancer Center, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Introduction: The standard of care for stage III colon cancer is 3 or 6 months of double-drug regimen chemotherapy following radical surgery. However, patients with positive circulating tumour DNA (ctDNA) exhibit a high risk of recurrence risk even if they receive standard adjuvant chemotherapy. The potential benefit of intensified adjuvant chemotherapy, oxaliplatin, irinotecan, leucovorin and fluoropyrimidine (FOLFOXIRI), for ctDNA-positive patients remains to be elucidated.
View Article and Find Full Text PDFSalvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
Anticancer Res
January 2025
Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Osaka, Japan.
Article Synopsis
- A study explored salvage chemotherapy using capecitabine plus oxaliplatin (XELOX) for gastric cancer patients who couldn't tolerate or were resistant to cisplatin, but it was halted due to low patient enrollment.
- 12 patients participated, revealing a disease control rate of 90% and a response rate of 30%, with median progression-free survival of 4.2 months and overall survival of 7.1 months.
- Common severe side effects included fatigue and low potassium levels, but there were no treatment-related deaths, suggesting XELOX might be beneficial for these patients.
Alternating Oxaliplatin and Irinotecan Chemotherapy Combined With Capecitabine and Bevacizumab for Microsatellite-stable Stage IV Metastatic Colon Cancer With a BRAF V600E Mutation: Two Case Reports Indicating Survival Improvement over Standard Therapy.
Anticancer Res
January 2025
Department of Integrated TCM & Western Medicine, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, P.R. China
Article Synopsis
- Colorectal cancer is the third most common cancer, and managing unresectable metastatic cases, especially those with MSS and BRAF V600E mutation, poses significant challenges for treatment.
- Two case reports illustrate the effectiveness of an alternating chemotherapy regimen (irinotecan and oxaliplatin along with capecitabine and bevacizumab) in two patients with MSS, BRAF V600E-mutated stage IV metastatic CRC, demonstrating a partial response and dropping carcinoembryonic antigen levels.
- The study suggests that this alternating regimen offers a promising treatment strategy with improved progression-free survival compared to standard first-line therapies, making it a potential first-line option for patients with this specific type of colorectal cancer.
A cerebral clue in the stomach: Brain lesion leads to discovery of hidden gastric cancer.
Int J Surg Case Rep
December 2024
Department of Radio Oncology, School of Medicine Cancer Prevention Research Center Seyyed Al-Shohada Hospital Isfahan University of Medical Sciences, Iran. Electronic address:
Article Synopsis
- Brain metastases from gastric adenocarcinoma are very rare, accounting for only 0.1-0.16% of cases, and can present significant diagnostic challenges, especially when neurological symptoms appear before gastrointestinal ones.
- An 82-year-old male experienced non-specific neurological symptoms and was ultimately diagnosed with brain metastasis from a primary gastric tumor through advanced imaging and biopsies, underscoring the complexity of diagnosis in such cases.
- The case illustrates the necessity for a thorough diagnostic process and a coordinated treatment approach involving chemotherapy and targeted radiation therapy to effectively manage complex cancer presentations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!